期刊文献+
共找到5篇文章
< 1 >
每页显示 20 50 100
Adult pancreatoblastoma: Current concepts in pathology 被引量:9
1
作者 Ayo O Omiyale 《World Journal of Gastroenterology》 SCIE CAS 2021年第26期4172-4181,共10页
Adult pancreatoblastoma is an exceptionally rare malignant tumour of the pancreas that mimics other solid cellular neoplasms of the pancreas,which may pose diagnostic difficulties.Because of its rarity,little is known... Adult pancreatoblastoma is an exceptionally rare malignant tumour of the pancreas that mimics other solid cellular neoplasms of the pancreas,which may pose diagnostic difficulties.Because of its rarity,little is known about its clinical and pathologic features.This article reviews the clinical and pathologic features of pancreatoblastoma in adults including differential diagnosis,treatment,and follow-up.Although pancreatoblastoma commonly occurs in childhood,there have now been more than 70 adult pancreatoblastomas described in the literature.There is a slight male predominance.There are no symptoms unique to pancreatoblastomas and adult patients are frequently symptomatic.The most common presenting symptom is abdominal pain.Grossly,the tumours are often large and well-circumscribed.Microscopically,pancreatoblastomas are composed of neoplastic cells with predominantly acinar differentiation and characteristic squamoid nests.These tumours are positive for trypsin,chymotrypsin,lipase,and BCL10.Loss of heterozygosity on chromosome 11p is the most common molecular alteration in pancreatoblastomas.Adult pancreatoblastomas are aggressive tumours with frequent local invasion,recurrence,and distant metastasis.Treatment consists of surgical resection.Chemotherapy and radiotherapy may have a role in the treatment of recurrent,residual,unresectable,and metastatic disease.It is important to distinguish pancreatoblastomas from morphological mimics such as acinar cell carcinomas,solid pseudopapillary neoplasms,and pancreatic neuroendocrine neoplasms. 展开更多
关键词 PANCREAS Adult pancreatoblastoma Pancreatic cancer Solid pancreatic mass non-ductal pancreatic tumours
下载PDF
Solid pseudopapillary neoplasm of the pancreas 被引量:9
2
作者 Ayo O Omiyale 《World Journal of Hepatology》 2021年第8期896-903,共8页
Solid pseudopapillary neoplasms are rare.This article reviews the clinical and pathologic features of solid pseudopapillary neoplasm of the pancreas,including the epidemiology,cytology,molecular pathology,differential... Solid pseudopapillary neoplasms are rare.This article reviews the clinical and pathologic features of solid pseudopapillary neoplasm of the pancreas,including the epidemiology,cytology,molecular pathology,differential diagnosis,treatment,and prognosis.Solid pseudopapillary neoplasms are low-grade malignant tumours of the pancreas characterized by poorly cohesive epithelial cells with solid and pseudopapillary patterns.Solid pseudopapillary neoplasms occur predominantly in young women.Although solid pseudopapillary neoplasms can occur throughout the pancreas,they arise slightly more frequently in the tail of the pancreas.The aetiology is unknown.Extremely rare cases have been reported in the setting of familial adenomatous polyposis.There are no symptoms unique to solid pseudopapillary neoplasms,however,the most common symptom is abdominal pain or discomfort.The features of solid pseudopapillary neoplasms on computed tomography imaging are indicative of the pathologic changes within the tumour.Typically,well-demarcated masses with variably solid and cystic appearances.Microscopically,these tumours are composed of epithelial cells forming solid and pseudopapillary structures,frequently undergoing haemorrhagic cystic degeneration.Typically,these tumours express nuclear and/or cytoplasmicβ-catenin.Almost all solid pseudopapillary neoplasms harbour mutations in exon 3 of CTNNB1,the gene encodingβ-catenin.The overall prognosis is excellent,and most patients are cured by complete surgical resection. 展开更多
关键词 Cancer of pancreas Pancreatic neoplasms Solid pseudopapillary neoplasm of the pancreas non-ductal pancreatic tumours PANCREAS
下载PDF
非肿块型DCIS影像学特点与临床病理特征及分子分型的相关性分析
3
作者 刘芳 周梦红 +3 位作者 王海娟 袁博 欧晓霞 李莉 《河北医学》 2024年第1期55-60,共6页
目的:探讨非肿块型乳腺导管内原位癌(DCIS)影像学特点,并分析影像学特点与临床病理特征及分子分型关系。方法:选取2020年6月至2021年6月在我院接受手术治疗的100例非肿块型DCIS患者作为研究对象,进行超声影像分分型,分别为Ⅰ型31例,Ⅱ... 目的:探讨非肿块型乳腺导管内原位癌(DCIS)影像学特点,并分析影像学特点与临床病理特征及分子分型关系。方法:选取2020年6月至2021年6月在我院接受手术治疗的100例非肿块型DCIS患者作为研究对象,进行超声影像分分型,分别为Ⅰ型31例,Ⅱ型15例、Ⅲ型43例及Ⅳ型11例。免疫组化检测病理组织雌激素受体(ER)、孕激素受体(PR)、人类表皮生长因子受体2(HER2)及Ki-67阳性表达;按照St.Gallen标准对患者进行Luminal A型及Luminal B型分子分型。结果:Ⅰ型:导管出现增粗,行走迂曲且管腔内出现低回声;Ⅱ型:乳腺内呈现片状的低回声区域,边界模糊;Ⅲ型:乳腺内呈现片状的低回声区域,可见分布不匀的点状强回声;Ⅳ型:乳腺内腺体及导管分布混乱,结构扭曲;Ⅰ型、Ⅱ型、Ⅲ型及Ⅳ型非肿块型DCIS患者临床病理资料年龄、肿瘤直径、月经状态、病灶部分、临床症状均无统计学差异(P>0.05),随着超声分型级别的升高细胞核分级也随之升高(P<0.05);Ⅰ型、Ⅱ型患者HER2阳性表达差异无统计学意义(P>0.05),与Ⅰ型相比,Ⅲ型及Ⅳ型的HER2阳性表达升高(P<0.05);与Ⅱ型相比,Ⅲ型的HER2阳性表达升高,但与Ⅳ型差异无统计学意义(P>0.05),Ⅲ型与Ⅳ型的HER2阳性表达组间比较差异无统计学意义(P>0.05);与Ⅰ型相比,Ⅲ型患者Luminal A型、Luminal B型分型分布升高(P<0.05),与Ⅰ型相比,Ⅳ型患者Luminal B型分型分布升高(P<0.05),Luminal A型差异无统计学意义(P>0.05)。结论:非肿块型DCIS患者超声主要为钙化型,认为结构紊乱型患者细胞核分级较高,且HER2阳性表达较多,Luminal A型占比降低,Luminal B型占比升高。 展开更多
关键词 非肿块型乳腺导管内原位癌 超声 分级 临床病理
下载PDF
超声造影及MRI对非肿块型DCIS临床特征及预后的诊断效能分析 被引量:1
4
作者 刘芳 周梦红 +3 位作者 易熙 袁博 欧晓霞 李莉 《中国医疗设备》 2023年第9期81-86,共6页
目的 探讨超声造影及MRI对非肿块型乳腺导管原位癌(Ductal Carcinoma in Situ,DCIS)临床特征及预后的诊断效能。方法 选取2021年1月至2023年11月于我院行超声造影及MRI检查的100例非肿块型DCIS患者,观察并记录超声造影及MRI诊断准确率,... 目的 探讨超声造影及MRI对非肿块型乳腺导管原位癌(Ductal Carcinoma in Situ,DCIS)临床特征及预后的诊断效能。方法 选取2021年1月至2023年11月于我院行超声造影及MRI检查的100例非肿块型DCIS患者,观察并记录超声造影及MRI诊断准确率,以及其评分与临床特征及预后的关系。结果 100例患者中,超声造影检测出非肿块型DCIS83例,准确率为83.00%(83/100),MRI检测出86例,准确率为86.00%(86/100),超声造影联合MRI检测出93例,准确率为93%(93/100)。非肿块型DCIS患者病理类型、淋巴结转移、组织学分级、细胞核分级的超声评分组间有明显差异(P<0.05);非肿块型DCIS患者病理类型、淋巴结转移、组织学分级、细胞核分级的MRI评分组间有明显差异(P<0.05)。与预后良好组比较,预后不良组超声造影评分及MRI评分显著升高,组间具有统计学差异(P<0.05);超声造影检测非肿块型DCIS的曲线下面积为0.790,MRI为0.834,两者联合为0.919。结论 超声造影及MRI对非肿块型DCIS临床特征及预后具有诊断价值,且联合诊断价值更高,可用于非肿块型DCIS临床特征的鉴别诊断及预后评估。 展开更多
关键词 超声造影 MRI 非肿块型乳腺导管原位癌 临床特征 预后
下载PDF
多模态MR成像在评估乳腺癌新辅助化疗疗效中的价值
5
作者 朱婷婷 李永姣 +3 位作者 冉强 罗青毅 刘衡 张体江 《中国CT和MRI杂志》 2023年第4期94-97,共4页
目的探讨3.0T多模态MR成像对乳腺癌新辅助化疗疗效评估的价值。方法连续性收集行全程新辅助化疗(NAC)并最终行手术治疗的51例非特殊型浸润性导管癌(NS-IDC)患者,分别于NAC前、化疗结束后1~2周内行多模态MR检查,测量并计算各参数值。根据... 目的探讨3.0T多模态MR成像对乳腺癌新辅助化疗疗效评估的价值。方法连续性收集行全程新辅助化疗(NAC)并最终行手术治疗的51例非特殊型浸润性导管癌(NS-IDC)患者,分别于NAC前、化疗结束后1~2周内行多模态MR检查,测量并计算各参数值。根据NAC前穿刺活检结果,分为分化较好组和分化较差组。按NAC后病理评估结果,分为组织学显著反应(MHR)组和组织学非显著反应(NMHR)组。探讨NAC前后两组癌灶最大径(D)、表观扩散系数(ADC)、平均扩散系数(MD)、平均扩散峰度(MK)值及其变化率的差异,分析各参数值与NAC疗效的相关性,使用受试者工作特征(ROC)曲线确定多模态MR成像参数对化疗疗效评估的诊断效能,并获得诊断临界点。结果显著反应组19例,非显著反应组32例。NAC后,两组病灶的D、ADC、MD、MK值及其变化率均有显著差异,且诊断效能较高。MR与病理测量最大径值呈高度正相关(r=0.912,P<0.01)。△MD%、△D%、△ADC%、△MK%预测疗效的ROC下面积分别为0.90、0.89、0.87、0.67,最佳临界预测值分别为21.15%、69.19%、55.30%、30.15%,评估的敏感性分别系94.7%、73.7%、63.2%、57.9%,特异性系78.1%、96.9%、96.9%、71.9%。结论应用多模态MR成像技术可从多方位探测肿瘤组织化疗前后动态变化特征,△MD%、△D%对乳腺癌NAC疗效评价具有较高的诊断价值。 展开更多
关键词 非特殊型浸润性导管癌 新辅助化疗 扩散加权成像 扩散峰度成像
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部